Great Ormand Street Hospital enters commercial agreement with Leucid Bio
pharmafile | March 16, 2023 | News story | Medical Communications |
Leucid Bio and Great Ormand Street Hospital NHS Foundation Trust (GOSH) have entered a commercial agreement to manufacture Leucid’s lead asset, LEU011, to treat solid tumours and haematological malignancies using facilities and quality assured services at the Zayed Centre for Research into Rare Disease in Children.
Leucid Bio is a biotech company focusing on finding a differentiated approach to the development of CAR-T cell therapies using its new Lateral CAR Platform, with the aim of improving treatment outcomes for patients with refractory cancers.
The agreement with GOSH involves the manufacturing of lead asset, LEU011, a lateral CAR targeting NKG2D ligands, for use in human clinical studies.
Both parties will retain the ownership of background IP, and Leucid is expected to own all intellectual Property Rights from the manufacturing services performed, although this is subject to contractual obligations.
Ian Miscampbell, interim executive chairman at Leucid Bio, commented: “We are extremely pleased to enter this first-of-its-kind agreement with GOSH to manufacture our lead asset, LEU011, for use in human studies. Additionally, we are pleased to have started a process with GOSH to examine the feasibility of applying our approach in the paediatric setting where there remains a great unmet need for new therapies. Working in close collaboration with leading institutes such as GOSH is fundamental to our ability to move quickly into clinical trials, using their state-of-the-art manufacturing facilities based here in London.”
Stephen Mathew, head of innovation at GOSH, added: “Gene and cell therapies are the cutting-edge in clinical research, holding promise to offer personalised cancer treatment, including for rare forms that affect children and young people. At Great Ormand Street Hospital, we see children with the most rare and complex cancers. There have been incredibly strides forward in the treatments that we can offer, however, sadly for many these still don’t work. Gene and cell therapies offer hope for better, and potentially curative treatments which is why we’re excited to support innovation in gene therapies through access to these highly specialist and unique facilities.”
Betsy Goodfellow
